Research
Our Research Advantage
Access to Facilities
Lighthouse operates under the benefit of an exclusive contract with Kragujevac University, granting the opportunity to conduct pre-clinical trials together with the Faculty of Medicine.
Scientific Infrastructure
Serbia is desirable jurisdiction for conducting medical research because of its unique combination of a very established scientific infrastructure alongside a relatively low standard of living
International Cooperation
Kragujevac University enjoys a great international co-operation network that includes Karolinska Institute in Stockholm as well as The First Moscow State Medical University, Russia , and other Serbian Medical Universities.
Cost Advantage
Lighthouse has calculated a significant cost advantage in conducting pre-clinical and clinical studies on psychedelic compounds compared to its peers as a result of this partnership.
Our World Class Research Team
Prof. Dr. Vladimir Jakovljevic, PhD
Dean of the Faculty of Medical Sciences University of Kragujevac
President of Serbian Physiological Society
Editor in Chief of Serbian Journal of Experimental and Clinical Research
20 years of research experience
148 publications, 538 citations in 80 journals globally
Prof. Tibor J. Sabo, PhD
University of Belgrade , Full Professor
Chair of General and Inorganic Chemistry
Award of the Serbian chemical society for outstanding success during studies
Over 120 Publications, 900 Citations , over 20 years of research experience
Our Leading Researchers
Ass. Prof. Biljana Ljujic, PhD
Ass. Professor of Human Genetics
Ass. Prof. MD, PhD Tamara Nikolic Turnic
Ass. Professor of Human Genetics
Molecule Research
Commercialization of novel mental health solutions
Lighthouse`s primary focus is the commercialization of novel mental health solutions designed at improving health outcomes for patients suffering from depression, post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders.
Design and Test
Lighthouse intends to design and test new molecule derivates from Psilocybin and Ibogaine.
Create Psilocybin
Lighthouse intends to first create five novel Psilocybin derivate molecules, and apply to patent each of them.
Create Ibogaine
Lighthouse intends to create an additional 5 novel Ibogaine derivate molecules, and apply to patent each of them.
Pre-clinical Trials
Lighthouse intends to commence 3 pre-clinical trials, studying its novel Psilocybin derivate molecules during 2021
Clinical Tests
Lighthouse intends to clinically test its new molecules with volunteer patients at The University of Zurich in 2022.
Lighthouse offers quick and highly cost effective molecular development and pre-clinical research in a peer reviewed GLP laboratory.
API Production
Production of pharmaceutical grade API’s
Lighthouse`s second focus is on the production of pharmaceutical grade API’s for sale to other accredited researchers and Institutions. Lighthouse will commence modest API production under license in Serbia with an anticipated larger facility in Montenegro. Lighthouse projects that it will have commenced API production and received all necessary export permits allowing for the export and sale of GLP pharmaceutical grade synthetic psilocybin in Serbia in late 2021, with operations in Montenegro anticipated to commence by the second quarter 2022.
A current need for API’s
Universities and research companies spreading across the globe require a reliable supply of pharmaceutical grade psychedelic ingredients.
An anticipated massive C.A.G.R.
As the industry develops the pharmaceutical and wellness industries will require an enormous supply of approved API`s to produce and administer psychedelic based substances.
An anticipated array of APIs
Lighthouse will work towards creating additional synthesized API’s including Ibogaine, Bufo, Ayahuasca and Kambo.
Surging global demand
In the coming years it is anticipated that global demand for GMP/GLP synthesized psychedelic API`s will far exceed available supply.
Lighthouse has a clear path to immediate revenue while it conducts pre clinical research on its own novel molecules.